Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

DEA Proposes Cutting Production of Come Opioids

Reuters Staff  |  August 7, 2017

(Reuters)—The U.S. Drug Enforcement Administration (DEA) on Friday proposed a 20% reduction in the manufacture of certain commonly prescribed opioid painkillers, as well as other controlled substances for next year. The proposal comes as U.S. regulators and lawmakers take steps to limit the supply of opioids—a class of drugs that include prescription painkillers and heroin—to…

Novel Bone Drug Promising in Postmenopausal Osteoporosis

Reuters Staff  |  August 7, 2017

NEW YORK (Reuters Health)—The investigational drug romosozumab led to gains in hip bone mineral density (BMD) that were not seen with teriparatide in older women with osteoporosis transitioning from bisphosphonate therapy in the STRUCTURE study. Amgen’s romosozumab is a monoclonal antibody that inhibits sclerosin, a negative regulator of bone formation. In addition to stimulating bone…

2017 Update of Treat-to-Target Recommendations for Axial & Peripheral SpA & PsA

Michele B. Kaufman, PharmD, BCGP  |  August 7, 2017

An international task force has updated recommendations for axial and peripheral spondyloarthritis, and psoriatic arthritis, which include treat-to-target recommendations…

Anti-TNF-Alpha Agents May Improve Endothelial Function Patients with RA

Lara C. Pullen, PhD  |  August 7, 2017

A systematic review has found that anti-tumor necrosis factor alpha treatment may improve endothelial function in RA patients. Despite the heterogeneity of the included studies, a random-effects model showed a significant improvement in endothelial function in this patient population after receiving infliximab, adalimumab or etanercept…

Hundreds of Diseases. One Voice.

Carina Stanton  |  August 5, 2017

Continually building awareness and understanding of rheumatic diseases is critical to both our profession and patient care, according to Kelly Weselman, MD, a rheumatologist in Smyrna, Ga., and a passionate advocate involved in planning the ACR’s annual Rheumatic Disease Awareness Month (RDAM). “Unlike cancer patients, whose disease is well known, patients battling a rheumatic disease…

When to Add a Rheumatologist to Your Practice

Karen Appold  |  August 4, 2017

Is a rheumatologist in your practice retiring? Do patients wait a long time for an appointment? Answering yes to these questions could mean it’s time to hire a new rheumatologist. Here are a few other considerations…

Senate Reauthorizes FDA to Collect Fees from Drugmakers

Reuters Staff  |  August 3, 2017

(Reuters)—The U.S. Senate on Thursday passed a bill allowing the Food and Drug Administration to continue collecting fees from drug companies to review new product applications. The FDA Reauthorization Act renews an existing law that expires on Sept. 30 and which provides the majority of FDA funds used to review pharmaceuticals and determine whether they…

Oversupply of Opioids after Surgery Helps Fuel Opioid Epidemic

Ronnie Cohen  |  August 3, 2017

(Reuters Health)—More than two-thirds of surgery patients in a recent study had prescription opioids left over after they recovered from their operations, and the vast majority failed to safely store or dispose of the often misused and abused pills, researchers say. “Unused opioids that have been prescribed for pain after surgery serve as an important…

ACR Supports Bill for Increased Medicare Contractor Transparency

Susan Bernstein  |  August 3, 2017

Working with more than 40 other medical associations, the ACR is supporting proposed federal legislation, the Local Coverage Determination Clarification Act of 2017 (S. 794). The bill is co-sponsored by Sens. Johnny Isakson (R-Ga.), Tom Carper (D-Del.), John Boozman (R-Ark.) and Debbie Stabenow (D-Mich.). The bill’s provisions would add transparency to how Medicare Administrative Contractors…

U.S. Governors Urge Trump to Make Health Insurance Payments

Reuters Staff  |  August 2, 2017

WASHINGTON (Reuters)—Democratic and Republican U.S. governors on Wednesday urged the Trump administration, as well as Congress, to continue funding payments to health insurance companies that make Obamacare plans affordable, calling it critical to stabilizing the insurance marketplace. In a statement, governors joined insurers pressuring Republican President Donald Trump to stand down from threats to cut…

  • « Previous Page
  • 1
  • …
  • 190
  • 191
  • 192
  • 193
  • 194
  • …
  • 317
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences